Adial Pharmaceuticals, Inc. WT EXP 073123
ADILW
NASDAQ Capital Market0.00
USD
+0.00
- -
CIK
0001513525
CUSIP
00688A114
Return %
Stock
S&P500
1Y
-98.28
26.53
3Y
-99.76
76.60
5Y
-99.82
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- None
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- DE United States of America
- IPO Date
- Jul 27, 2018
- CIK
- 0001513525
- Similar Companies
- Business
- Adial Pharmaceuticals, Inc. Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing genetically targeted therapies for the treatment and prevention of addiction disorders and related conditions; its lead product candidate, AD04, is a selective serotonin-3 receptor antagonist in Phase 3 clinical development for alcohol use disorder (AUD) in patients with specific genotypes identified via the company's proprietary companion diagnostic genetic test. The company also advances an adenosine-based platform originally from its acquisition of Purnovate, targeting non-opioid pain reduction, cocaine addiction, and other indications such as asthma through licensed assets. Adial Pharmaceuticals operates primarily in the biotechnology sector, serving patients with addiction and unmet medical needs through precision medicine approaches, with a pipeline spanning discovery through Phase 3 stages. Founded in 2010 following research from the University of Virginia initiated in the 1990s, Adial Pharmaceuticals is headquartered in Glen Allen, Virginia, and conducts operations in the United States with global patent protection for AD04 extending through 2032 and potential extensions. The company went public on NASDAQ in 2018 (Ticker: ADIL) and maintains a lean team of approximately five employees focused on clinical trial execution, regulatory strategy, and partnerships. Recent developments include a strategic collaboration with Boudicca Dx to advance the regulatory pathway for its companion diagnostic test ahead of AD04's Phase 3 trials, enhancing FDA validation for patient selection; engagement with Cytel's machine learning technology for optimized data analysis and adaptive Phase 3 trial design, positioning topline readouts for late 2025; and a monetization deal with Adovate following the 2023 sale of Purnovate assets, yielding a six-figure milestone payment in May 2025 upon Phase 1 initiation of ADO-5030 for asthma, plus eligibility for up to $83 million in future milestones, low single-digit royalties, and over 10% equity retention. In June 2025, Adial completed a $3.6 million public offering of shares and warrants (including Series D and E) to fund working capital and general corporate purposes amid ongoing AD04 advancement post-ONWARD Phase 3 completion in 2022. Additionally, the company appointed a new CFO in late 2024 to support strategic growth and expanded AD04's potential applications to opioid use disorder, gambling, and obesity.